Merck Drug Meets Survival Goal in Stomach Cancer Trial
Phase 3 TroFuse-015 trial showed improved overall survival versus physician's choice treatment in third-line gastroesophageal adenocarcinoma.
Updated on Nov. 22, 2026 in Cancer

Merck announced that its global Phase 3 TroFuse-015 trial met its primary overall survival endpoint for sacituzumab tirumotecan in patients with third-line or later gastroesophageal adenocarcinoma. The progression-free survival secondary endpoint was not met, and the drug is not approved for any use.
Why it matters
The result offers a survival benefit signal for patients with limited options after multiple prior treatments, a population Merck described as having a tremendous unmet need. Because the announcement did not include hazard ratios, median survival values or p-values, the size of the benefit cannot yet be independently assessed.
The announcement reports a statistically significant overall survival gain over physician's choice therapy in the TroFuse-015 Phase 3 trial, with objective response rate nominally higher but not formally tested. Hazard ratios, median survival values and p-values were not disclosed, and the full results and meeting venue have yet to be shared.
The players
Merck
Merck is a major global pharmaceutical company headquartered in the United States that runs the TroFuse clinical development programme and holds the rights to sacituzumab tirumotecan outside Greater China.
Kelun-Biotech
Kelun-Biotech is a Chinese biopharmaceutical company that developed sacituzumab tirumotecan and granted Merck an exclusive licence outside Greater China.
The details
The trial enrolled adults with measurable disease who had progressed after at least two prior lines of therapy and had an ECOG performance status of 0 or 1, and TROP2 expression was not required for enrolment. Merck reported that safety was consistent with previous sacituzumab tirumotecan studies with no new safety signals, and the drug was developed by Kelun-Biotech, with Merck holding rights outside Greater China under an exclusive licence.
Timeline
November 20, 2026: Merck announced TroFuse-015 met its overall survival endpoint.
June 15, 2027: FDA target action date for sacituzumab tirumotecan in endometrial cancer.
Health Landscape
TroFuse-015 is the second positive Phase 3 readout in Merck's TroFuse programme, which runs 18 ongoing global Phase 3 trials enrolling more than 15,000 patients. The result adds a survival-focused data point to a programme whose broader ambition is to bring the antibody-drug conjugate into multiple cancer types.
Patients with gastroesophageal adenocarcinoma who have already progressed after multiple lines of therapy have no approved use of this drug yet, so no change to treatment options is possible until a regulator acts. The trial result is a clinical signal, not an available therapy, and patients should discuss any trial enrolment with their oncology team.
The takeaway
A statistically significant survival gain in a hard-to-treat population is a meaningful early signal, but the lack of published effect sizes means readers should await full data before judging clinical value. Progression-free survival was not met, so the benefit is best understood as overall survival alone until more detail emerges.
What happens next
Merck says full TroFuse-015 results will be presented at an upcoming medical meeting it has not named and shared with regulatory authorities. The FDA target action date for sacituzumab tirumotecan in endometrial cancer is June 15, 2027.
Further reading
For background on the disease at the centre of this trial, see Cancer coverage on Wisevoter.
More information
Review the trial record in the ClinicalTrials.gov registry entry for TroFuse-015.
Source note: This article includes information reported by CASRAI.



